02 July 1997
Shares in Hungtingdon fall
Shares in Huntingdon Life Sciences dived 15% to 55.5p after the
company issued a profits warning.
Huntingdon said it had disappointing new orders which would leave
profits for the year to December substantially below last years
Huntingdon is a controversial company because of its involvement in
testing drugs on animals. Glaxo Wellcome and Zeneca have recently
withdrawn their business. Christopher Cliffe, chief executive, said the
company would occur a small loss in the first half after providing 1m
for additional costs relating to allegations. He expected the group to
return to profit in 1997.